Takeda Pharmaceutical Li... (TKPHF)

PNK: TKPHF · Real-Time Price · USD

29.85

-2.28 (-7.10%)

At close: Apr 30, 2025, 3:48 PM

Takeda Pharmaceutical Income Statement

Financials in JPY. Fiscal year is April - March.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017	Mar 31, 2016
Revenue	4,263.8B	4,027.5B	3,569B	3,197.8B	3,291.2B	2,097.2B	1,770.5B	1,732.1B	1,807.4B
Cost of Revenue	1,431.5B	1,244.1B	1,106.8B	994.31B	1,089.8B	659.69B	495.92B	558.75B	535.4B
Gross Profit	2,832.3B	2,783.4B	2,462.2B	2,203.5B	2,201.4B	1,437.5B	1,274.6B	1,173.3B	1,272B
Operating Income	214.07B	490.5B	460.84B	509.27B	100.41B	204.97B	241.79B	155.87B	130.83B
Interest Income	11.29B	62.91B	23.7B	105.52B	27.83B	6.62B	39.54B	12.27B	21.64B
Pretax Income	52.79B	375.09B	302.57B	366.24B	-60.75B	94.9B	217.21B	143.35B	120.54B
Net Income	144.07B	317.02B	230.06B	376B	44.24B	109.13B	186.89B	114.94B	80.17B
Selling & General & Admin	1,053.8B	997.31B	886.36B	875.66B	964.74B	717.6B	628.11B	619.06B	650.77B
Research & Development	729.92B	633.33B	526.09B	455.83B	492.38B	368.3B	325.44B	312.3B	345.93B
Other Expenses	834.44B	-9.47B	-20.72B	-19.49B	-30.41B	4.11B	n/a	n/a	6.39B
Operating Expenses	2,618.2B	2,292.9B	2,001.3B	1,694.2B	2,101B	1,277.2B	1,032.8B	1,017.4B	1,141.1B
Interest Expense	119.53B	169.7B	166.61B	248.63B	165.01B	48.16B	31.93B	23.25B	31.93B
Selling & Marketing Expenses	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Cost & Expenses	4,049.7B	3,537B	3,108.2B	2,688.5B	3,190.8B	1,936.9B	1,528.7B	1,576.2B	1,676.5B
Income Tax Expense	-91.41B	58.05B	72.41B	-9.94B	-105.04B	-14.12B	30.5B	27.83B	37.06B
Shares Outstanding (Basic)	1.56B	1.55B	1.56B	1.56B	1.56B	961.48M	780.81M	781.1M	783.94M
Shares Outstanding (Diluted)	1.58B	1.57B	1.58B	1.57B	1.57B	966.9M	786.71M	785.89M	788.18M
EPS (Basic)	92.09	204.29	147.14	240.72	28.41	113.50	239.35	147.15	102.26
EPS (Diluted)	91.16	201.94	145.87	238.96	28.25	112.86	237.55	146.25	101.71
EBITDA	900.33B	1,156.5B	1,183.2B	983.72B	880.33B	464.22B	359.96B	296.88B	349.85B
EBIT	172.33B	492.06B	425B	497.04B	88.26B	175.77B	227.24B	150.91B	152.47B
Depreciation & Amortization	728B	664.4B	583.15B	559.67B	583.65B	247.69B	182.13B	171.43B	181.24B